Chitosan and its derivatives in mucosal drug and vaccine delivery.

Numerous studies have demonstrated that chitosan and their derivatives (N-trimethyl chitosan, mono-N-carboxymethyl chitosan) are effective and safe absorption enhancers to improve mucosal (nasal, peroral) delivery of hydrophylic macromolecules such as peptide and protein drugs and heparins. This absorption enhancing effect of chitosans is caused by opening of the intercellular tight junctions, thereby favouring the paracellular transport of macromolecular drugs. Chitosan nano- and microparticles are also suitable for controlled drug release. Association of vaccines to some of these particulate systems has shown to enhance the antigen uptake by mucosal lymphoid tissues, thereby inducing strong systemtic and mucosal immune responses against the antigens. The aspecific adjuvant activity of chitosans seems to be dependent on the degree of deacetylation and the type of formulation. From the studies reviewed it is concluded that chitosan and chitosan derivatives are promising polymeric excipients for mucosal drug and vaccine delivery.

[1]  Gerrit Borchard,et al.  The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: Effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro , 1996 .

[2]  I Saiki,et al.  Immunological activity of chitin and its derivatives. , 1984, Vaccine.

[3]  J. Kreuter,et al.  Influence of crosslinking on the acid stability and physicochemical properties of chitosan microspheres , 1996 .

[4]  H. Junginger,et al.  Macromolecules as safe penetration enhancers for hydrophilic drugs—a fiction? , 1998 .

[5]  H. Junginger,et al.  Effect of degree of quaternization of N-trimethyl chitosan chloride for enhanced transport of hydrophilic compounds across intestinal caco-2 cell monolayers. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[6]  R. Muzzarelli.  Chitosan-based dietary foods , 1996 .

[7]  R. Rappuoli,et al.  A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. , 2000, Vaccine.

[8]  M. Alonso,et al.  Design of microencapsulated chitosan microspheres for colonic drug delivery. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[9]  M. Risbud,et al.  Chitosan-Polyvinyl Pyrrolidone Hydrogel does Not Activate Macrophages: Potentials for Transplantation Applications , 2001, Cell transplantation.

[10]  H. Junginger,et al.  Chitosans for enhanced delivery of therapeutic peptides across intestinal epithelia: in vitro evaluation in Caco-2 cell monolayers , 1997 .

[11]  I. Azuma,et al.  Adjuvant activity of chitin derivatives in mice and guinea-pigs. , 1985, Vaccine.

[12]  H. Junginger,et al.  Intestinal absorption of octreotide: N-trimethyl chitosan chloride (TMC) ameliorates the permeability and absorption properties of the somatostatin analogue in vitro and in vivo. , 2000, Journal of pharmaceutical sciences.

[13]  D. McCarthy,et al.  Nanosphere and microsphere uptake via Peyer's patches: observation of the rate of uptake in the rat after a single oral dose , 1992 .

[14]  A. Perkins,et al.  Evaluation of the clearance characteristics of bioadhesive systems in humans. , 1999, International journal of pharmaceutics.

[15]  M. Alonso,et al.  Investigation of a pMDI system containing chitosan microspheres and P134a , 1998 .

[16]  S. Davis,et al.  Nasal administration of morphine-6-glucuronide in sheep--a pharmacokinetic study. , 1996, Biopharmaceutics & drug disposition.

[17]  J. Akbuğa,et al.  Chitosan beads for the delivery of salmon calcitonin : preparation and release characteristics , 1996 .

[18]  S. Davis,et al.  Novel chitosan-based delivery systems for the nasal administration of a LHRH-analogue , 2000 .

[19]  L. Tetley,et al.  Liposomes encapsulating polymeric chitosan based vesicles--a vesicle in vesicle system for drug delivery. , 2000, International journal of pharmaceutics.

[20]  Cenk Aral,et al.  Alternative approach to the preparation of chitosan beads , 1998 .

[21]  María J. Alonso,et al.  Development of a freeze-dried formulation of insulin-loaded chitosan nanoparticles intended for nasal administration , 1999 .

[22]  I. Kwon,et al.  Novel mucosal immunization with polysaccharide-protein conjugates entrapped in alginate microspheres. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[23]  Q. Myrvik,et al.  Alveolar macrophage priming by intravenous administration of chitin particles, polymers of N-acetyl-D-glucosamine, in mice , 1997, Infection and immunity.

[24]  V. Dodane,et al.  Pharmaceutical applications of chitosan , 1998 .

[25]  H. Junginger,et al.  Enhancement of paracellular drug transport with highly quaternized N-trimethyl chitosan chloride in neutral environments: in vitro evaluation in intestinal epithelial cells (Caco-2). , 1999, Journal of pharmaceutical sciences.

[26]  W. Paul,et al.  Chitosan, a drug carrier for the 21st century : a review , 2000 .

[27]  H. Kaş.  Chitosan: properties, preparations and application to microparticulate systems. , 1997, Journal of microencapsulation.

[28]  H. Junginger,et al.  Chitosan for enhanced intestinal permeability: prospects for derivatives soluble in neutral and basic environments. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[29]  M. Costantini,et al.  Influence of glutaraldehyde on drug release and mucoadhesive properties of chitosan microspheres , 1998 .

[30]  Y. Murata,et al.  Preparation of alginate gel beads containing chitosan salt and their function , 1999 .

[31]  W. Park,et al.  Blood compatibility and biodegradability of partially N-acylated chitosan derivatives. , 1995, Biomaterials.

[32]  L. Illum,et al.  Chitosan and its use as a pharmaceutical excipient. , 1998, Pharmaceutical research.

[33]  J L Pedraz,et al.  Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[34]  R. Rappuoli,et al.  Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. , 1998, Vaccine.

[35]  J. Eyles,et al.  Oral and nasal immunization with microencapsulated clinically relevant proteins , 1998 .

[36]  S. Aiba.  Studies on chitosan: 4. Lysozymic hydrolysis of partially N-acetylated chitosans. , 1992, International journal of biological macromolecules.

[37]  H. Junginger,et al.  Effects of N-trimethyl chitosan chloride, a novel absorption enhancer, on caco-2 intestinal epithelia and the ciliary beat frequency of chicken embryo trachea. , 1999, International journal of pharmaceutics.

[38]  D. Cremaschi,et al.  Selective transport of microparticles across Peyer's patch follicle‐associated M cells from mice and rats , 1995, Experimental physiology.

[39]  A. Mitra,et al.  Chitosans as nasal absorption enhancers of peptides: comparison between free amine chitosans and soluble salts. , 2000, International journal of pharmaceutics.

[40]  H. Junginger,et al.  Mono-N-carboxymethyl chitosan (MCC), a polyampholytic chitosan derivative, enhances the intestinal absorption of low molecular weight heparin across intestinal epithelia in vitro and in vivo. , 2001, Journal of pharmaceutical sciences.

[41]  P. G. Seferian,et al.  Immune stimulating activity of two new chitosan containing adjuvant formulations. , 2000, Vaccine.

[42]  H E Junginger,et al.  Chitosan microparticles for oral vaccination: preparation, characterization and preliminary in vivo uptake studies in murine Peyer's patches. , 2001, Biomaterials.

[43]  P. Couvreur,et al.  Mucosal immunogenicity elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly (D,L-lactide-co-glycolide) microspheres. , 1998, Vaccine.

[44]  M. Alonso,et al.  Novel hydrophilic chitosan‐polyethylene oxide nanoparticles as protein carriers , 1997 .

[45]  S. Davis,et al.  In vitro evaluation of the mucoadhesive properties of chitosan microspheres , 1998 .

[46]  P. Perugini,et al.  Evaluation of process parameters involved in chitosan microsphere preparation by the o/w/o multiple emulsion method. , 1996, Journal of microencapsulation.

[47]  Krishnendu Roy,et al.  Oral gene delivery with chitosan–DNA nanoparticles generates immunologic protection in a murine model of peanut allergy , 1999, Nature Medicine.

[48]  J. Kreuter,et al.  Preparation and characterization of chitosan microspheres as drug carrier for prednisolone sodium phosphate as model for anti-inflammatory drugs , 1996 .

[49]  R. Duncan,et al.  Evaluation of the biological properties of soluble chitosan and chitosan microspheres , 1997 .

[50]  H E Junginger,et al.  In Vivo Uptake of Chitosan Microparticles by Murine Peyer's Patches: Visualization Studies using Confocal Laser Scanning Microscopy and Immunohistochemistry , 2001, Journal of drug targeting.

[51]  J. Iida,et al.  Stimulation of non-specific host resistance against Sendai virus and Escherichia coli infections by chitin derivatives in mice. , 1987, Vaccine.

[52]  M. Roberts,et al.  Carbohydrate Biopolymers Enhance Antibody Responses to Mucosally Delivered Vaccine Antigens , 2000, Infection and Immunity.

[53]  Thomas R. Tice,et al.  Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches , 1990 .